<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000785</url>
  </required_header>
  <id_info>
    <org_study_id>CPCRA 017</org_study_id>
    <secondary_id>11568</secondary_id>
    <nct_id>NCT00000785</nct_id>
  </id_info>
  <brief_title>A Registry of Tuberculosis Cases in the CPCRA</brief_title>
  <official_title>A Registry of Tuberculosis Cases in the CPCRA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY: To estimate the proportion of tuberculosis patients in the CPCRA who have
      drug-resistant tuberculosis (TB) and to describe the patterns of drug resistance.

      SECONDARY: To compare drug resistance data on the Mycobacterium tuberculosis isolates of
      HIV-infected patients to those of HIV-uninfected patients who are being followed in the
      CPCRA. To assess the relationship of resistance data with geographic, demographic, and HIV
      and TB risk factor information.

      Geographic areas and demographic subgroups affected by the TB epidemic appear to be
      congruent and associated with the concurrent HIV epidemic. The total number of CPCRA
      patients who will develop, or who have experienced, confirmed TB is unknown. It is critical
      to determine the depth and breadth of the current problem of drug-resistant TB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Geographic areas and demographic subgroups affected by the TB epidemic appear to be
      congruent and associated with the concurrent HIV epidemic. The total number of CPCRA
      patients who will develop, or who have experienced, confirmed TB is unknown. It is critical
      to determine the depth and breadth of the current problem of drug-resistant TB.

      For both retrospective and prospective components of the study, demographic, geographic, HIV
      and TB risk factor information will be collected on CPCRA patients with confirmed pulmonary
      or extrapulmonary TB. Mycobacterial culture results will be recorded. Retrospective data
      will be collected on CPCRA patients with confirmed tuberculosis who have been diagnosed
      since January 1992 until the time of site registration. Prospective data will be collected
      on CPCRA patients with confirmed tuberculosis diagnosed during the period of 1 to 2 years
      following site registration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1992</start_date>
  <completion_date type="Actual">June 1994</completion_date>
  <primary_completion_date type="Actual">June 1994</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Cross-Sectional</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1509</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>All eligible CPCRA subjects</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Any sample that can be used to test for M.tuberculosis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible CPCRA subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients must meet the following criteria:

          -  CPCRA patients with confirmed pulmonary or extrapulmonary TB. Confirmed clinical TB
             requires a positive culture for Mycobacterium tuberculosis.

        NOTE:

          -  There is no requirement that patients have HIV infection.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Gordin</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Denver CPCRA / Denver Public Hlth</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr / Regional AIDS Program</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Alliance - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Comm AIDS Rsch Prog / Tulane Univ Med</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive AIDS Alliance of Detroit</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Jersey Community Research Initiative</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hosp Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addiction Research and Treatment Corp</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Directors Network of Region II</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gordin FM, Nelson ET, Matts JP, Cohn DL, Ernst J, Benator D, Besch CL, Crane LR, Sampson JH, Bragg PS, El-Sadr W. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med. 1996 Nov;154(5):1478-83.</citation>
    <PMID>8912768</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 28, 2013</lastchanged_date>
  <firstreceived_date>November 2, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Mycobacterium tuberculosis</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Drug Resistance, Microbial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
